Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes

Figure 4

Effects of the robust model on patient outcome in TCGA cohort. (a) The risk score analysis is from top to bottom: patient’s risk distribution, gene expression profile, and survival status map. (b) The Kaplan–Meier survival curves for patients with bladder cancer in TCGA, stratified according to risk scores (high vs. low); comparisons of the median survival time in both groups with log-rank tests (). (c) ROC curve analysis of the prognostic accuracy of the model in TCGA. (d–i) The subgroups’ Kaplan–Meier’s analysis of risk score.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)